Cargando…

972. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients Supported on Extracorporeal Membrane Oxygenation (ECMO)

BACKGROUND: ECMO provides life-saving cardiac and/or pulmonary support to critically ill patients, but its effects on the PK of many antimicrobials remain unknown. Herein, we describe the PK of imipenem (IMI) and relebactam (REL) in critically ill patients supported on ECMO. METHODS: Patients with c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fratoni, Andrew J, Kois, Abigail, Gluck, Jason A, Nicolau, David P, Kuti, Joseph L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678008/ http://dx.doi.org/10.1093/ofid/ofad500.027

Ejemplares similares

1087. Imipenem-Cilastatin-Relebactam (I/R) Pharmacokinetics (PK) in Critically Ill Patients with Augmented Renal Clearance (ARC)
por: Fratoni, Andrew J, et al.
Publicado: (2021)

1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)
por: Kois, Abigail K, et al.
Publicado: (2021)

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022)

1309. Imipenem/Cilastatin/Relebactam (I/R) Alone and in Combination against Pseudomonas aeruginosa (PSA) in the In Vitro Pharmacodynamic Model
por: Chen, Iris H, et al.
Publicado: (2020)

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections
por: Heo, Young-A.
Publicado: (2021)

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Brown, Michelle, et al.
Publicado: (2018)

Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
por: Rizk, Matthew L., et al.
Publicado: (2018)

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia
por: Patel, Munjal, et al.
Publicado: (2021)

Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach
por: Ghazi, Islam M., et al.
Publicado: (2020)

Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
por: Rebold, Nicholas, et al.
Publicado: (2021)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
por: Naik, Jaesh, et al.
Publicado: (2023)

Correction: Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach
por: Ghazi, Islam M., et al.
Publicado: (2020)

Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections: A Meta-analysis
por: Sahra, Syeda, et al.
Publicado: (2021)

Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants
por: Rhee, Elizabeth G., et al.
Publicado: (2018)

Comments on the Published Meta-Analysis of Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections
por: Vaziri, Ali Zaman, et al.
Publicado: (2021)

Reply: Comments on the Published Meta-Analysis of Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections
por: Jahangir, Abdullah, et al.
Publicado: (2021)

Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms
por: Yang, Joe, et al.
Publicado: (2022)

1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Kaye, Keith, et al.
Publicado: (2018)

Correction to: Cost-Effectiveness of Imipenem/Cilastatin/Relebactam Compared with Colistin in Treatment of Gram-Negative Infections Caused by Carbapenem-Non-Susceptible Organisms
por: Yang, Joe, et al.
Publicado: (2022)

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections
por: Bhagunde, Pratik, et al.
Publicado: (2019)

1460. Imipenem/Cilastatin (IMI)/Relebactam (REL) in Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia (HABP/VABP): Subgroup Analyses of Critically Ill Patients in the RESTORE-IMI 2 Trial
por: Chen, Luke F, et al.
Publicado: (2020)

Imipenem-cilastatin-induced psychosis: a case report
por: Ninan, Jacob, et al.
Publicado: (2016)

Genomic Characterization of Imipenem- and Imipenem-Relebactam-Resistant Clinical Isolates of Pseudomonas aeruginosa
por: López-Pérez, Mario, et al.
Publicado: (2021)

Activity of imipenem/relebactam on Klebsiella pneumoniae with different mechanisms of imipenem non-susceptibility
por: Mashaly, Mervat El-Sayed, et al.
Publicado: (2021)

1159. Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Pediatric Participants With Confirmed or Suspected Gram-negative Bacterial Infections: A Phase 1b, Open-label, Single-Dose Clinical Trial
por: Bradley, John S, et al.
Publicado: (2021)

Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin
por: Agudelo, Maria, et al.
Publicado: (2019)

Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance
por: Roberts, Jason A, et al.
Publicado: (2023)

Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus
por: Lopeman, Rose C., et al.
Publicado: (2020)

Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia
por: Choi, Jun Yong, et al.
Publicado: (2006)

A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date
por: Campanella, Toni A, et al.
Publicado: (2020)

In Vitro Antibacterial Activity of Imipenem/Relebactam against Clinical Isolates in Japan
por: Kurihara, Dai, et al.
Publicado: (2022)

Metabolic alkalosis: A less appreciated side effect of Imipenem-cilastatin use
por: Panda, Pragyan Swagatika, et al.
Publicado: (2013)

Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
por: Kabbara, Wissam K, et al.
Publicado: (2015)

Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
por: Shaaban, Mona I., et al.
Publicado: (2017)

Small bowel bleeding treated successfully with transcatheter arterial embolization with imipenem/cilastatin
por: Arima, Takahiro, et al.
Publicado: (2022)

1230. Clinical and Microbiologic Outcomes by Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated with Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ)
por: Losada, Maria C, et al.
Publicado: (2020)

Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
por: Sagan, Olexiy, et al.
Publicado: (2020)

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
por: Young, Katherine, et al.
Publicado: (2019)

Author Correction: Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus
por: Lopeman, Rose C., et al.
Publicado: (2020)

Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy
por: Jang, Soo Min, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qt5pkv63ofpfr6si09g06p5dkt